Ping Ji Biography and Net Worth

Director of Adlai Nortye

Ping Ji serves as our director. She has over 25 years of experience in biopharmaceutical drug development.

Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol-Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation.

Dr. Ji obtained her master of medicine from the cell biology program offered jointly by Graduated School-New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ-Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986.

What is Ping Ji's net worth?: The estimated net worth of Ping Ji is at least $2.06 million as of September 22nd, 2026. Ms. Ji owns 131,667 shares of Adlai Nortye stock worth more than $2,056,112 as of September 24th. This net worth evaluation does not reflect any other investments that Ms. Ji may own. Learn More about Ping Ji's net worth.
How do I contact Ping Ji?: The corporate mailing address for Ms. Ji and other Adlai Nortye executives is 77 Robinson Road, #20-01, Robinson 77, Singapore, 068896. Adlai Nortye can also be reached via phone at 848-230-7430 and via email at [email protected]. Learn More on Ping Ji's contact information.
Has Ping Ji been buying or selling shares of Adlai Nortye?: During the past quarter, Ping Ji has sold $83,150.00 in Adlai Nortye stock. Most recently, Ping Ji sold 5,000 shares of the business's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $16.63, for a transaction totalling $83,150.00. Following the completion of the sale, the director now directly owns 131,667 shares of the company's stock, valued at $2,189,622.21. Learn More on Ping Ji's trading history.
Who are Adlai Nortye's active insiders?: Adlai Nortye's insider roster includes Ping Ji (Director), Yang Lu (CEO), and Xiaofeng Ye (CFO). Learn More on Adlai Nortye's active insiders.
Are insiders buying or selling shares of Adlai Nortye?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 16,677 shares worth more than $247,916.55. The most recent insider tranaction occured on September, 22nd when Director Ping Ji sold 5,000 shares worth more than $83,150.00. Learn More about insider trades at Adlai Nortye.
Information on this page was last updated on 9/22/2026.

Ping Ji Insider Trading History at Adlai Nortye

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/22/2026	Sell	5,000	$16.63	$83,150.00	131,667

Ping Ji Buying and Selling Activity at Adlai Nortye

Adlai Nortye Company Overview

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $15.86

$14.70

$16.05

50 Day Range

MA: $13.89

$11.35

$16.60

2 Week Range

Now: $15.86

$0.88

$17.25

Volume

130,577 shs

Average Volume

373,181 shs

Market Capitalization

$1.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04